HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a global leader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing.
On October 28, 2025, HTL Biotechnology hosted its first-ever webinar, “Shaping the Future of Aesthetic Medicine with Premium Biopolymers,” a key initiative to strengthen our presence in Asia and promote the “Feel the Difference with HTL Inside” positioning among major players in aesthetic medicine.
This October, HTL Biotechnology turned pink to support breast cancer prevention.
HTL Biotechnology is the winner of the Responsible Care West Atlantic Trophy in the ‘Energy – Climate’ category for its project to reduce carbon emissions from distillation systems.